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Background: Although common risk factors for venous thromboembolism (VTE) are well known, little data exist
concerning the clinical impact of VTE in postoperative patients outside of controlled studies. This study evaluated
prospective perioperative demographic and clinical variables associated with occurrence of postoperative symptomatic
VTE.
Methods: Demographic and clinical data were collected on surgical patients undergoing nine common general, vascular,
and orthopedic operations presenting to the Veterans Health Administration Hospitals between 1996 and 2001 as part
of the National Surgical Quality Improvement Program (NSQIP). The association between covariates and the incidence
of postoperative symptomatic VTE (includes deep venous thrombosis and pulmonary embolism) was assessed using
bivariable and multivariable regression.
Results:Complete demographic and clinical information for analysis were available for 75,771 patients. The mean patient
age was 65 years, and 96.6% were men. Major comorbidities included diabetes mellitus (DM), 25%; chronic obstructive
pulmonary disease (COPD), 18.3%; and congestive heart failure (CHF), 3.9%. Symptomatic VTE was diagnosed in 805
patients (0.68%), varied significantly with procedure (0.14% for carotid endarterectomy vs 1.34% for total hip
arthroplasty), and was associated with increased 30-day mortality (16.9% vs 4.4%, P< .0001). The incidence of VTE did
not decline substantially between 1996 and 2001 (0.72% vs 0.68%). Preoperative factors associated with symptomatic
VTE were older age, male gender, corticosteroid use, COPD, recent weight loss, disseminated cancer, low albumin, and
low hematocrit (all P < .01) but not DM. Postoperative factors associated with VTE were myocardial infarction (MI),
blood transfusion (>4 units), coma, pneumonia, and urinary tract infection (UTI), whereas those with hemodialysis-
dependent renal failure were less likely to experience VTE (all P < .01). In multivariable analysis, adjusting for age and
the variables significant by bivariable analysis, the strongest positive predictors of symptomatic VTE included UTI (odds
ratio [OR], 1.8; 95% confidence interval [CI], 1.3 to 2.5), acute renal insufficiency (OR, 1.9; 95% CI, 1.1 to 3.2),
postoperative transfusion (OR, 2.3; 95% CI, 1.4 to 3.7), perioperative MI (OR, 2.4; 95% CI, 1.5 to 3.9), and pneumonia
(OR, 2.7; 95% CI, 2.1 to 3.5 ). In contrast, hemodialysis (OR, 0.3; 95% CI, 0.07 to 0.71), DM (OR, 0.75; 95% CI, 0.61
to 0.93), and higher preoperative albumin levels (OR, 0.8; 95% CI, 0.74 to 0.96, per mg/dL change) were protective
from symptomatic VTE.
Conclusions: Although the overall incidence of symptomatic VTE is low in surgical patients, it is associated with
significantly increased 30-day mortality. In addition to previously recognized risk factors, patients who have postoper-
ative complications of an infectious nature, bleeding, or MI are at particular risk. ( J Vasc Surg 2007;45:335-42.)Venous thromboembolism (VTE) has become a better
recognized significant cause of morbidity and mortality in
the United States, with an estimated incidence of 118/
100,000 person-years.1 Indeed, a Surgeon General’s con-
ference was convened in May 2006 to discuss the impor-
tance of VTE (personal communication, T Wakefield).
Similarly, the National Institutes of Health have put forth
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involving venous thrombosis and its complications.
The concept of VTE risk stratification has also gained
greater recognition, with major insurers and organiza-
tions of quality-of-care improvement such as the Joint
Commission of Accreditation of Healthcare Organiza-
tions (JCAHO), the National Quality Forum, and the
Surgical Care Improvement Program (all accessible at www.
jointcommission.org/PerformanceMeasurement). Specifi-
cally, these bodies mandate the evaluation, risk stratifica-
tion, and implementation of VTE prophylaxis for all
hospitalized patients.
Common risk factors for VTE have been well estab-
lished and include older age, presence of malignancy, prior
deep vein thrombosis (DVT), surgery or trauma, hyperco-
agulable disorders, certain medications such as oral contra-
ceptives and estrogen replacement therapies, and possibly
obesity.2-4 Most of these factors can be determined by a
thorough history on admission and in preoperative plan-
ning. Indeed, excellent consensus guidelines exist to deter-
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Elderly surgical patients with medical comorbidities are
generally at high risk for VTE, and aggressive prophylaxis,
such as mechanical and anticoagulant prophylaxis, is man-
dated in their care. Rates of compliance vary, but several
studies suggest compliance with prophylaxis is low andmay
be the primary preventable cause of VTE.1,6 Even with
aggressive VTE prophylaxis, however, this event still occurs
and suggests other undefined factors may play a role in VTE
occurrence.
Two recent studies highlight the risks and outcomes for
postoperative symptomatic VTE. The @RISTOS registry
included 2373 patients with malignancy undergoing sur-
gery. Although prophylaxis was documented in nearly 85%,
and the incidence of VTE was 2.1%, VTE was directly
associated with death in 43%.7 Supporting this study was a
review by our own group of the administrative database,
the Nationwide Inpatient Sample, that showed postopera-
tive symptomatic VTE occurrence in cardiovascular opera-
tive patients was associated with nearly threefold increased
risk of death, significantly increased cost, and length of stay
(American Venous Forum 2006, unpublished data).
From this background, we sought to determine the
epidemiology, risk factors, and impact of postoperative
symptomatic VTE in a defined surgical real-world patient
population using the prospective and standardized Na-
tional Surgical Quality Improvement Program (NSQIP)
data from the Department of Veterans Affairs (VA) Hospi-
tal system.
METHODS
The study population comprised veterans’ treated in
VA hospitals whose preoperative and postoperative data
were tracked by the NSQIP, which has been described
previously.8,9 In brief, the NSQIP is an ongoing prospective
cohort study of surgical patients presenting to Veterans
Health Administration (VHA) hospitals that was instituted
in 1994 for the purposes of providing feeding back to the
VA medical centers of risk-adjusted surgical outcomes for
quality improvement, and supported by VHA Patient Care
Services. For the current analysis, the cohort comprised
118,258 men and women who underwent one of nine
common surgical procedures: nonruptured abdominal aor-
tic aneurysm repair, infrainguinal vascular reconstruction,
carotid endarterectomy, colectomy, open cholecystectomy,
laparoscopic cholecystectomy, lobectomy/pneumonectomy,
total hip replacement, or amputation, as derived from ap-
propriate current procedural terminology (CPT) codes.10
The procedures took place at 120 major VA hospitals
between 1996 and 2001. The Ann Arbor Veteran’s Hos-
pital Institutional Review Board approved this study.
Exposure and outcome measures. Potential risk fac-
tors for VTEwere initially determined at baseline by trained
nurse reviewers. The NSQIP database includes 45 preop-
erative, 17 intraoperative, and 33 outcome standardized
variables. In addition to age, gender, and race, the variables
selected for analysis were based on commonality or relation
to comorbidities and included the preoperative laboratoryvalues for concentrations of serum sodium, blood urea
nitrogen, creatinine, alkaline phosphate, serum glutamic-
oxaloacetic transaminase, bilirubin, and albumin; hemato-
crit and white blood cell and platelet counts; and serum
prothrombin time and partial thromboplastin time.
Preoperative clinical variables include smoking status
(active in past year, total pack-years), congestive heart
failure (CHF) 30 days before surgery, history of diabetes
mellitus (DM) treated with oral hypoglycemic drugs or
insulin, chronic obstructive pulmonary disease (COPD),
stroke with or without neurologic deficit, transient ische
mic attacks (TIA), disseminated cancer, weight loss 10%
body weight6 months of surgery, corticosteroid medica-
tion for a chronic condition, ventilator dependence 48
hours of surgery, preoperative transfusion of 4 units of
packed red blood cells (PRBCs), and ongoing requirement
for hemodialysis, listed as hemodialysis-dependent renal
failure (HDRF).
Postoperative characteristics including the occurrence
of cardiac arrest 30 days, myocardial infarction, coma,
stroke, pneumonia, urinary tract infection (UTI), acute
renal insufficiency (ARI; postoperative increase of 2
mg/dL creatinine), acute renal failure (ARF; need for
postoperative hemodialysis); transfusion 4 units PRBCs
72 hours after surgery, and total operative time (hours).
The primary end point for this analysis was a first
occurrence symptomatic VTE, defined as either deep vein
thrombosis (DVT) or pulmonary embolism (PE). Diagno-
sis of DVT was confirmed by a positive report of venous
ultrasound imaging or venography, whereas the diagnosis
of PE was considered confirmed in the presence of either a
positive pulmonary angiogram or a ventilation-perfusion
scan with high probability. Note that computed tomo-
graphic angiography was not routinely used during this
time of data collection.
Statistical analysis. Bivariable analyses examined the
whole population of 118,258 patients. Wilcoxon rank-sum
and 2 tests were used to compare baseline distributions of
continuous variables and proportions according to the oc-
currence of all VTE, and separately for DVT and PE. The
number of patients missing exposure information for each
covariate considered is listed in the Appendix (online only).
We used unconditional logistic regression analysis to
determine the crude odds ratio (OR) of incident VTE30
days of surgery for each covariate considered. Those covari-
ates found to be statistically significant (at P  .05) risk
factors for VTE in the bivariable analysis were considered
candidates for multivariable analysis. The 75,771 patients
with complete information for all significant bivariable risk
factors for VTE (except smoking history, which was coded
using the missing indicator method) were considered in the
multivariable analyses.
The effect of potential confounders was assessed by com-
paring a crude-adjusted and maximally adjusted multiple-
adjusted OR for each covariate. The maximally adjusted
model was created by including all statistically significant
predictors of VTE from the bivariable analysis. A more
parsimonious final multivariable model was developed by
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forced into the final model, otherwise the entry and stay
criteria were P  .20 and P  .05, respectively.
To assess for the influence of potential outliers amongst
continuous variables, the bivariable analysis was repeated
excluding values greater than three standard deviations
above the mean. To assess for deviation from linearity, we
compared the likelihood ratio of the model for trend with
that of a model that included indicator variables for each
quartile of age. The relation between the occurrence of
VTE and 30-day mortality was explored using a multivari-
able logistic model, adjusting for age, and all covariates that
were significant (P .05) predictors of 30-day mortality in
crude logistic analysis. All analyses used the SAS 9.1 statis-
tical package (SAS Institute, Cary, NC).
RESULTS
Demographics, preoperative, and postoperative
events of the whole population. At baseline, the mean
age among the 118,258 study participants was 65 years,
and 96.6%weremen. Comorbidities includedCHF (3.9%),
DM (25%), a history of TIAs (8%), disseminated cancer
(2%), COPD (18.3%), and HDRF (1.7%). Current or past
tobacco use was documented in 65%. The mean operative
time of all cases was 2.9  2 hours. Postoperative compli-
cations included pneumonia (3.5%), UTI (2.7%), cardiac
arrest (1.4%), myocardial infarction (0.86%), bleeding re-
quiring a transfusion 4 units (0.8%), and ARI (0.6%).
Symptomatic venous thromboembolism during
follow-up. During a follow-up period of 30 days, 805
documented VTEs occurred (0.68%). Of these, 545 were
solely DVT and 260 were PE, including 34 patients who
had both. The occurrence of VTE varied according to
procedure type, with carotid endarterectomy having the
lowest incidence, and total hip arthroplasty had the highest
incidence, with a tenfold difference (P  .0001; Table I).
The VTE incidence over the time of the interval studied did
not significantly change, with a similar proportion of DVT
Table I. Venous thromboembolism incidence and
relative risk
Procedure VTE incidence (%) OR* (95% CI)
CEA 0.14 1
Cholecystectomy
Laparoscopic 0.19 1.8 (1.0-3.0)
Open 0.48 3.7 (2.2-6.3)
Amputation 0.61 4.8 (3.0-7.7)
Lobe/pneumonectomy 0.72 5.2 (3.2-8.3)
LE bypass 0.87 5.4 (3.5-8.3)
AAA 0.94 5.6 (3.4-9.4)
Colectomy 0.94 6.4 (4.2-9.8)
THA 1.3 10.3 (6.7-15.7)
Overall 0.68
VTE, venous thromboembolism; OR, odds ratio; CI, confidence interval;
CEA, carotid endarterectomy; LE, lower extremity; AAA, abdominal aortic
aneurysm; THA, total hip arthroplasty.
*Adjusted odds ratio for age and operative time.and PE occurring each year (P  .92; Fig).Factors associated with symptomatic venous throm-
boembolism bivariable analysis. Both preoperative and
postoperative patient variables were associated with VTE
occurrence. Increased age (mean, 67 vs 65 years; P .001)
andmale vs female gender (0.60% vs 0.40%; P .026) were
positively associated with VTE. Patients with preoperative
HDRF, TIAs, and DM were less likely to sustain VTE than
if these factors were not present (Table I). Conversely, p a -
tients taking corticosteroids, those with a history of dis-
seminated cancer, unintended 10% weight loss, COPD,
and transfusion had a significantly higher incidence of VTE
postoperatively. Preoperative laboratory indicators that
correlated with VTE included a lower mean albumin (3.60
vs 3.46 mg/dL; P .0001) and hematocrit (39.1 vs 38.5;
P  .005). Patient factors that were not associated with an
increased incidence of VTE included platelet counts, race,
history of cerebrovascular accident, preoperative pneumo-
nia, preoperative ventilator use, preoperative renal failure,
CHF, or length of stay.
Those patients who sustained a VTE had longer oper-
ative times (2.9 vs 3.5 hours, a difference of 0.5 hours).
Postoperative complications were highly associated with
VTE (Table II) Those patients who had a cardiac arrest,
MI, stroke, bleeding (4 U transfusion), coma, ARF, and
ARI were more likely to have a VTE compared with those
without those complications. Similarly, the infectious com-
plications of UTI and pneumonia were three to five times
more common in those patients with a VTE.
Multivariable analysis of factors associated with
symptomatic venous thromboembolism, deep venous
thrombosis, pulmonary embolism, and death. The re-
sults of the stepwise logistic regression are summarized in
Table III. The final multivariable model showed that
HDRF, DM, and a normal albumin concentration were
protective against VTE. However, increased age, operative
time, weight loss 10%, corticosteroid use, UTI, and ARI
Fig. Incidence of deep venous thrombosis (DVT), pulmonary
embolism (PE), and venous thromboembolism (VTE) (DVT 
PE), from 1996 to 2001.all increased the risk of VTE by onefold to twofold. The
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postoperative hemorrhage requiring transfusion (4 U),
MI, cardiac arrest, and pneumonia. Note that tobacco use,
coma, disseminated cancer, and ARF were not indepen-
dently associated with VTE.
Because of the large patient numbers, an additional
multivariable analysis was done to evaluate factors associ-
ated with DVT and PE, separately (Table IV). The risk of
DVT was reduced in those patients with normal albumin
levels and DM. Increased operative time, postoperative
Table II. Preoperative and postoperative factors
associated with venous thromboembolism
Factor VTE (%) OR 95% CI P
Preoperative
HDRF 0.15 0.22 0.07-0.69 .009
TIA 0.40 0.55 0.39-0.77 .001
Diabetes mellitus 0.60 0.80 0.67-0.95 .012
Tobacco use ever 0.70 1.00 1.00-1.004 .016
COPD .90 1.45 1.23-1.70 .0001
Transfuse 4 U 1.16 1.73 1.08-2.77 .022
Corticosteroids 1.20 1.87 1.37-2.53 .0001
Weight loss 10% 1.30 2.01 1.60-2.54 .0001
Dissem cancer 1.50 2.27 1.63-3.17 .0001
Postoperative
UTI 1.90 2.98 2.29-3.89 .0001
Stroke 1.91 2.87 1.68-4.89 .0001
ARF 2.10 3.12 1.83-5.32 .0001
MI 2.64 4.06 2.75-5.99 .0001
ARI 2.70 4.08 2.57-6.46 .0001
Cardiac arrest 2.92 4.61 3.42-5.21 .0001
Pneumonia 2.93 5.02 4.13-6.10 .0001
Transfuse  4U 3.00 4.61 3.15-6.76 .0001
Coma 3.68 5.43 2.55-11.6 .0001
VTE, venous thromboembolism; OR, odds ratio; CI, confidence interval;
HDRF, hemodialysis-dependent renal failure; TIA, treatment ischemic at-
tack; COPD, chronic obstructive pulmonary disease; UTI, urinary tract
infection; ARF, acute renal failure; MI, myocardial infarction; ARI, acute
renal insufficiency.
Table III. Independent factors associated with venous
thromboembolism
Factor OR 95% CI P
HDRF 0.23 0.07-.71 .01
DM 0.75 0.61-.93 .01
Alb (per mg/dL) 0.84 0.74-.96 .008
Age (per year) 1.01 1.00-1.02 .008
Increased Op time (per hr) 1.1 1.07-1.16 .0001
Weight loss 1.4 1.10-1.90 .009
Corticosteroid 1.5 1.10-2.20 .02
UTI 1.8 1.3-2.50 .0006
ARI 1.9 1.09-3.2 .023
Transfusion 4 U 2.3 1.40-3.70 .0007
MI 2.4 1.50-3.90 .0003
Cardiac arrest 2.5 1.70-3.60 .0001
Pneumonia 2.7 2.10-3.50 .0001
OR, odds ratio; CI, confidence interval; HDRF, hemodialysis-dependent
renal failure; DM, diabetes mellitus; Alb, albumin; UTI, urinary tract infec-
tion; ARI, acute renal insufficiency; MI, myocardial infarction.UTI, pneumonia, and bleeding (4 U) conferred a signif-icant independent risk for DVT (Table IV). The factors
independently associated with PE that were different than
those associated with DVT included age (no longer signif-
icant after forcing smoking into the model), corticosteroid
use, and cardiac arrest (Table IV).
The crude mortality rate was significantly higher in
those patients who suffered a VTE (16.9% vs 4.4%, P 
.0001). Multiple independent factors were associated with
30-day mortality (Table V). The occurrence of VTE, in our
data, was a strong independent predictor of 30-day mortal-
ity. The effect of VTE was in the mid range of factors
associated with death. Namely, VTE conferred a greater
risk of death than did CHF, HDRF, and bleeding (4 U)
but less than pneumonia, MI, ARI, or cardiac arrest.
DISCUSSION
The current study shows that postoperative symptom-
atic VTE occurs at a low but consistent rate during this
TABLE IV. Independent factors associated with deep
venous thrombosis and pulmonary embolism
Factor OR 95% CI P
Deep venous thrombosis
Alb (per mg/dL) 0.80 0.68-0.94 .007
DM 0.71 0.53-0.96 .03
Increased Op time (per hr) 1.1 1.09-1.20 .0001
UTI 1.7 1.07-2.80 .030
Pneumonia 2.5 1.70-3.70 .0001
Transfusion 4 U 3.3 1.80-6.10 .0001
Pulmonary embolism
Age (per year) 1.02 1.001-1.03 .043
UTI 2.0 1.1-3.4 .02
Corticosteroid 2.0 1.1-3.6 .02
Transf  4 U 2.4 1.1-5.3 .03
Pneumonia 3.9 2.6-6.0 .0001
Cardiac arrest 7.6 4.8-11.9 .0001
OR, odds ratio; CI, confidence interval; Alb, albumin; DM, diabetes melli-
tus; UTI, urinary tract infection.
Table V. Independent factors associated with mortality
Factor* OR 95% CI P
UTI 0.5 0.40-.66 .001
Diabetes mellitus 0.88 0.78-.99 .04
Albumin 0.5 0.46-.53 .0001
CHF 1.3 1.12-1.57 .001
HDRF 1.6 1.29-2.1 .0001
Transfusion 4 U 1.7 1.27-2.4 .0001
Pneumonia 2.6 2.2-3.0 .0006
MI 4.2 3.2-5.5 .0001
ARI 7.6 5.7-9.9 .0001
Cardiac arrest 104 85-128 .0001
VTE 2.4 1.7-3.5 .0001
OR, odds ratio; CI, confidence interval; UTI, urinary tract infection; CHF,
congestive heart failure; HDRF, hemodialysis-dependent renal failure; MI,
myocardial infarction; ARI, acute renal insufficiency; VTE, venous throm-
boembolism.
*29 total independent variables.recent time interval. Further, the factors that have greatest
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ative complications such as bleeding and myocardial infarc-
tion and postoperative infections such as pneumonia and
UTI. The occurrence of postoperative VTE confers more
than a twofold increased risk of death, similar to other
major postoperative complications. Other prospective
studies in surgical patients have shown similar VTE risk
factors to our study, including increasing age, prior VTE,
operative time 2 hours, and bedrest.7 Similarly, older
medical patients with CHF or respiratory failure have in-
creased VTE risk.11
The incidence of symptomatic VTE in this group of
patients is lower than that in therapeutic trials and lower
than in historical studies of patients without prophylaxis.2,5
It must be emphasized that in the current study, DVT and
PE were clinically defined as being symptomatic and con-
firmed by the nurse abstractors from standardized criteria
of positive imaging studies and alerted to by the patients’
clinical picture. Clinical trials of anticoagulant prophylaxis
primarily use venographically defined DVT, and thus the
sensitivity is greater and many asymptomatic DVT are
found. For example, in a recent comparative prophylaxis
trial in high-risk general surgery patients, venographically
defined DVT was 4% to 6% higher than the current study.12
Although a strength of these data is that they were
collected with defined standardized definitions, including
events that occurred at institutions outside of the VA
hospitals, events that occurred 30 days were not cap-
tured. Certainly, VTE do occur outside of this time frame,
especially in those with malignancy and orthopedic proce-
dures.3,13
A relatively low symptomatic VTE incidence was doc-
umented in the current study, but there was no decrease in
the incidence of VTE during the study interval. This sug-
gests that little practice change regarding VTE prophylaxis
has occurred. A “one size fits all” for VTE prophylaxis may
not be the best approach, however. For example, although
a postoperative patient undergoing a lobectomy may be at
a given risk strata, depending on multiple comorbidities,
where anticoagulant prophylaxis is recommended, others
may require this prophylaxis and more, depending on the
number of risk factors. Patient level-specific VTE risk is not
well established, but the more factors that are deciphered,
the closer this goal may be. Indeed, with the VHA having a
fully electronic order entry, admission prophylaxis recom-
mendations as “pop-ups” are standard in many but not all
system hospitals (unpublished data). Electronic notifica-
tion has been shown to significantly improve prescription of
VTE prophylaxis as well as being associated with decreased
VTE events.14 The neglect of preoperative risk assessment
may thus be less of a problem in the future.
Preoperative variables that were associated with post-
operative VTE were several, but often are not modifiable.
Some factors by bivariable analysis were not surprising,
such as increased age, disseminated cancer, and significant
weight loss (probably a surrogate for malignancy or chronic
illness) and are well known.5 However, low albumin con-
centration, although well described in correlating withmortality in several studies,6,10,15,16 was also associated
with increased VTE risk. The reasons for this might be
chronic inflammation or generalized malnutrition that al-
ters liver synthetic function.Hypothetically, natural protein
anticoagulants such as antithrombin may be produced in
less than homeostatic quantities and tip the balance to-
wards a procoagulant state in conjunction with the normal
increased procoagulant postoperative state.
DM was protective from both VTE occurrence as well
as mortality. Although DM certainly confers a long-term
increased risk of mortality, this may not be the case perio-
peratively.10 Diabetic patients have increased risk of arterial
occlusive disease, but there is no known association of DM
and VTE. Hemodialysis-dependent operative patients also
had decreased VTE risk. The systemic inhibition of platelet
function that occurs with renal failure along with the hep-
arin anticoagulation that is often used during hemodialysis
may be the reason these patients were protected from VTE.
Consistent with this notion is that postoperative ARI was
associated with increased risk of VTE, whereas those re-
quiring postoperative hemodialysis did not have an in-
creased VTE risk.
Postoperative complications played a large role in pre-
dicting symptomatic VTE occurrence. As such, these
events may be an area where preventative measures can be
implemented. Most notably, the infectious complications
of pneumonia and UTI conferred a 2.7-fold and 1.8-fold
increase in VTE risk, respectively. We speculate that these
infectious processes set up a generalized state of inflamma-
tion. Others have also suggested this, as evidenced by the
increased risk of VTE in patients with inflammatory bowel
disease.17 Inflammation is both caused by and promotes
venous thrombosis as well as inhibits fibrinolysis at the
systemic and local level.18-20 A recent study of outpatients
with acute respiratory infections and UTIs were found to
have a significantly increased risk for VTE occurrence 1
month after treatment.21 In a study of patients with malig-
nancy, infection was associated with nearly fivefold in-
creased risk of VTE.22 It is also possible that patients in
whom pneumonia and UTI develop may be less active and
in bed, thus increasing VTE risk via a stasis mechanism.
Further support of the systemic inflammation associa-
tion with VTE occurrence is that postoperative MI was
associated with a 2.4-fold increased risk of VTE. Others
have shown a similar correlation.23 This might be counter-
intuitive, as these patients often receive heparin as part of
their treatment. However, the strong systemic inflamma-
tory response may override the anticoagulation benefit.
Prandoni et al24 have shown a strong correlation between
atherosclerosis and VTE. Also indirectly supportive of the
arterial-venous vascular inflammation is suggested by a
study that showed patients taking statin agents had a small
but significantly lower risk of VTE.25 We, however, were
not able to directly ascertain when these complications
occurred in relation to each other; that is, whether the VTE
occurred before or after other attendant complications.
Of interest was that PE had several different risk factor
associations compared withDVT.Others have shownmed-
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failure are at high risk for PE.26-28 There were no protective
factors for PE, unlike DVT. Also, and more interesting, is
that corticosteroids were associated with PE but not DVT.
It may be that these mediations reduce the natural inflam-
matory response that is essential for the DVT to adhere and
lyse.18 An alternative explanation is that the threshold to
obtain imaging studies for PEmay have been lower in those
patients taking corticosteroids for severe COPD, and
asymptomatic PE may have been more readily diagnosed.
Transfusions of blood also have a significant immunosup-
pressive effect and may promote less DVT adherence to the
vein wall, although transfusions were also independently
associated with DVT. Further investigation is needed into
DVT biology to better allow predictions of those at risk for
PE from a DVT.
The occurrence of VTE has a significant impact on
mortality. Indeed, any complication confers a significantly
increased long-term risk of death.10 Others have found a
significant early and late effect of VTE on mortality.29 How
often the VTE accounted for a patient’s cause of death in
this study was not able to be discerned. Certainly, the high
concordance of cardiac arrest and PE suggests these factors
are interrelated, but a direct cause–effect relationship can-
not be made. However, from a prospective registry study of
surgical patients with malignancy, VTE accounted for 43%
of deaths at the 1-year follow-up.7
Limitations to the current study are several. First, we
were unable to determine the patients’ specific VTE pro-
phylaxis (if any). Given that overall symptomatic VTE
occurrence was less than historical or controlled clinical
trials, we speculate VTE prophylaxis was fairly well pre-
scribed, although many asymptomatic VTEs may not have
been captured in this study. Second, no direct history of
hypercoagulable disorders or VTE history was obtained
from the patients. These are well documented risks associ-
ated with VTE after surgery,2,5 and we cannot exclude the
possibility that these variables would not have changed our
analysis. However, the strongest independent factors asso-
ciated with VTE were postoperative events such as pulmo-
nary or urinary tract infection. Also, women are few in the
VHA population, and the defined risk factors may not
extrapolate to this gender. Third, no information was
present about the timing of different postoperative compli-
cations. Finally, only 30-day perioperative data are captured
by NSQIP, and other reports have suggested benefit for
prolonged anticoagulation after surgery, as VTEmay occur
up to 90 days after the inciting event in oncology and
orthopedic patients.13,21,29 However, this group did not
make up the majority of the current cases in this series.
One direct implication of these data is that in patients
with a postoperative infectious or inflammatory complica-
tion, increased vigilance and more aggressive VTE prophy-
laxis should be considered. For example, an anticoagulant
should probably be added to the regimen of a patient who
has undergone a colectomy, develops pneumonia, and is
receiving only mechanical DVT prophylaxis. Whether infe-
rior vena cava filters should be used in the highest-riskpatients is controversial.2,30 Similarly, rigorous adherence
to the basics to prevent these infections is a must; namely,
strict urinary catheter hygiene, elevation of the head of the
bed to prevent aspiration, and aggressive pulmonary toi-
lette.
All operative patients should be assessed for VTE risk,
but not all patients need any significant prophylaxis outside
of ambulation the first day, such as laparoscopic cholecys-
tectomy and carotid endarterectomy. This has also been
confirmed in patients with breast cancer, where the VTE
risk was very rare.31 Thus, although preoperative risk strat-
ification and prophylaxis is important, close vigilance of
those patients with postoperative bleeding, infectious com-
plication, or MI is an area where further reductions in the
devastating complication of VTE can be made.
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Dr Peter Gloviczki (Rochester, Minn). The orthopedic sur-
geons frequently send patients to us to remove varicose veins
because they are worried that those patients will develop deep vein
thrombosis. In the Olmsted County epidemiology study, John
Heit from the Mayo Clinic found that in young patients, varicosity
was a predictor of deep vein thrombosis. So my question to you,
did you look at this risk factor, and in any of the surgical groups was
varicosity a risk factor of deep vein thrombosis?
Dr Peter Henke. In this series, certainly, varicose vein exci-
sion is done in the VA system, but it was not included in this patient
data set. So the simple answer is I’m not sure if this is a risk factor
for postoperative VTE.
Dr Jan Brunkwall (Bonn, Germany). I was a little bit sur-
prised about your message that diabetes mellitus and dialysis
should be protective against thromboembolism. Because in previ-
ous studies, when we investigated renal transplant patients, espe-
cially the diabetics were the ones that had an increased risk of
getting a thromboembolism afterwards. Do you have any explana-
tion for that?
Dr Henke. Not right offhand. I think that patients who are
undergoing hemodialysis may get some protection from the hep-
arin that’s used during their dialysis run. They also have a func-
tional antiplatelet effect from their often-elevated BUN, so that
may be the explanation there. With diabetes, it may be that they
have a relative inactivity of their leukocytes, and thus this may
decrease a potential proinflammatory component to thrombogen-diabetes was protective in mortality. And we know diabetics long
term have higher chances of death than nondiabetics. So it may be
a statistical aberration as well.
Dr Michael Maxwell (Mesa, Ariz). Did you distinguish be-
tween different types of DVT, for example, popliteal DVT versus
iliofemoral thrombus? Did the two groups differ in their results?
Dr Henke. The definitions with the NSQIP do not differen-
tiate between those two types of DVT.
Dr Alan Lumsden (Houston, Tex). Clearly, the strength of
the NSQIP database is the size and the scope of the hospitals that
are involved. The Achilles heel, of course, is the accuracy of the
diagnosis of venous thromboembolic disease. This is largely a
database of discharge diagnosis with 30-day follow-up.
Dr Henke. That’s correct, but it is not an administrative data
set. The VTE diagnosis is confirmed by an ultrasound report of
DVT, or with pulmonary embolism, either by pulmonary angiog-
raphy or two or more segment VQ mismatch by trained nurse
reviewers.
Dr Lumsden. Clearly, there are a variety of patients and a
variety of different centers. Do you have any sense of how the
diagnosis was established rather than just basically how the ICD-9
codes are being reported?
DrHenke.Again, with theNSQIP database, theDVT and PE
are prospectively acquired after the surgical procedure and do not
rely on ICD-9 codes.
Dr Lumsden. One last question. If you get an aortic aneu-
rysm, you’re in the hospital for 7 days. If you get a laparoscopic
cholecystectomy, you may be discharged the following day. Does
JOURNAL OF VASCULAR SURGERY
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hospitalization, independent of the magnitude of the procedure?
In other words, are you just more likely to get diagnosed with a
symptomatic DVT if you happen to be in the hospital at the time?
Dr Henke. Good question. Again, we did not specifically
look at length of stay versus the risk of VTE. Certainly if you
have complications such as pneumonia, UTI, myocardial infarc-
tion, your length of stay also increases, and it may be hiddenso if a VTE occurs as an outpatient, they are almost always
captured.
Dr Anton Sidawy (Washington, DC). As a follow-up to Dr.
Lumsden’s question, I wonder whether this manuscript’s title
should be changed to include the word “symptomatic” to qualify
DVT, because obviously you are not screening asymptomatic
patients in this study; the diagnosis is made on symptomatic
patients.within those variables. But, all patients are followed for 30 days, Dr Henke. Very good point. I agree.
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Variable Patients variable missing (n)
Age 0
Sex 0
Race 432
Preoperative
Albumin 36361
Alkaline phosphatase 42394
Bilirubin 35664
BUN 6343
Creatinine 8652
Length of stay 5890
Platelets 8681
Prothrombin time 43455
PTT 40294
SGOT 41465
Sepsis 4895
Sodium 8777
White blood cells 2404
Hematocrit 2251
History of
CHF 12
COPD 6
CVA with neuro deficit 4895
CVA w/o neuro deficit 4894
TIA attack 4899
Diabetes mellitus 4887
Disseminated cancer 7
Ventilator 10
Dialysis 4994
ARF 4994
Transfusion 4U 9
Operative time 11
Postoperative
MI 0
Cardiac arrest 0
Coma 0
Stroke 0
Transfusion 0
Pneumonia 0
UTI 0
ARF 0
ARI 0
BUN, Blood, urea, nitrogen; PTT, partial thromboplastin time; SGOT,
serum glutamic-oxaloacetic transaminase; CHF, congestive heart failure;
COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular acci-
dent; TIA, transient ischemic attack; ARF, acute renal failure; MI, myocar-
dial infarction; UTI, urinary tract infection; ARI, acute renal insufficiency.
